Antithrombotic activity of AT-1015, a potent 5-HT2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time

European Journal of Pharmacology

Volumn 433, Issue 2-3, 2001, Pages 157-162

  Kihara, Hideaki ^a   Koganei, Hajime ^a   Hirose, Ken ^a   Yamamoto, Hiroshi ^a   Yoshimoto, Ryota ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Arterial thrombosis; Bleeding time; Platelet aggregation; Vascular contraction

Indexed keywords

ANTITHROMBOCYTIC AGENT; LONG ACTING DRUG; N [2 [4 (5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE)PIPERIDINO]ETHYL] 1 FORMYLISONIPECOTAMIDE; SARPOGRELATE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY CONSTRICTION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMORAL ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION;

ANIMALS; BLEEDING TIME; FIBRINOLYTIC AGENTS; ISONIPECOTIC ACIDS; MALE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 0035930832     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01432-7     Document Type: Article

References (20)

1. Inhibition of platelet aggregation by a new agent, ticlopidine
2. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries
3. Retrospective analyses for hypothesis generation. A commentary on the PACK trial (prevention of atherosclerotic complications with ketanserin)
4. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist
5. Bleeding time in rats: A comparison of different experimental conditions
6. Local effect of serotonin released during coronary angioplasty
7. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models
8. Platelet activation and serotonin
9. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats
10. ADP plays a key role in thrombogenesis in rats
11. Evidence for a role of serotonin in initiation of coronary arterial thrombosis in dog and man
12. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function
13. Vessel wall injury and arterial thrombosis induced by a photochemical reaction
14. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022
15. Comparison of the inhibitory effects of the TxA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: Possible role of TxA2
16. Serotonergic receptor subtypes and vascular reactivity
17. The PACK trial: Morbidity and mortality effects of ketanserin. Prevention of atherosclerotic complications
18. Serotonin is associated with coronary artery disease and cardiac events
19. Serotonin release into plasma during common carotid artery thrombosis in rats
20. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin